BOWIE, Md., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq:INOV), a leading technology company providing advanced, cloud-based analytics and data-driven intervention platforms to the healthcare industry, today announced that Keith Dunleavy, M.D., Inovalon’s chief executive officer and chairman of the board, will present at the 33rd NASDAQ Investor Program along with Thomas Kloster, chief financial officer and Dan Rizzo, chief innovation officer.
The presentation will take place at the May Fair Hotel in London at 9:30 a.m. GMT (4:30 a.m. EST) on Tuesday, Dec. 1, 2015. An archived webcast of Inovalon’s presentation will be available for a limited time and will be accessible at www.inovalon.com under the “Investors” section.
Inovalon is a leading technology company that combines advanced, cloud-based data analytics, and data-driven intervention platforms to achieve meaningful insight and impact in clinical and quality outcomes, utilization, and financial performance across the healthcare landscape. Inovalon's unique achievement of value is delivered through the effective progression of Turning Data into Insight, and Insight into Action®. Large proprietary datasets, advanced integration technologies, sophisticated predictive analytics, data-driven intervention platforms, and deep subject matter expertise deliver a seamless, end-to-end capability that brings the benefits of big data and large-scale analytics to the point of care. Driven by data, Inovalon uniquely identifies gaps in care, quality, data integrity, and financial performance – while bringing to bear the unique capabilities to resolve them. Providing technology that supports hundreds of healthcare organizations in 98.2% of U.S. counties and Puerto Rico, Inovalon's cloud-based analytical and data-driven intervention platforms are informed by data pertaining to more than 777,000 physicians, 266,000 clinical facilities, and more than 127 million Americans. Through these capabilities, and those of its subsidiary Avalere Health, Inc., which offers data-driven advisory services and business intelligence to more than 200 pharmaceutical and life sciences enterprises, Inovalon is able to drive high-value impact, improving quality and economics for health plans, ACOs, hospitals, physicians, consumers and pharma/life-sciences researchers. For more information, visit www.inovalon.com.
Contacts: Inovalon Kim E. Collins Phone: 301-809-4000 x1473 email@example.com
Source:Inovalon Holdings, Inc.